

Special Issue

New Advance in Viral Immunogens and Vaccines

Message from the Guest Editors

The COVID-19 pandemic caused by SARS-CoV-2 has brought unprecedented challenges, significantly impacting our day-to-day lives. A vast amount of scientific literature has been produced to study the biology of the virus and the pathophysiology of COVID-19 to determine the best way to prevent infection. At the beginning of an immune response formation to SARS-CoV-2, the first step is the exposure of human cells to the virus, the process then setting its course in both the major histocompatibility complex (MHC) class I and II direction and the direct natural killer (NK) cell activation. Previous clinical and epidemiological studies have shown that, over time, antibody titers vanish, and do not provide long-term mucosal protection against SARS-CoV-2 infection, with some recent studies suggesting that the sustained cellular immune response plays a critical role in long-term protection in individuals recovering from SARS-CoV-2 and after vaccination. We hope this Special Issue will help in answering some of the many still unanswered questions regarding COVID-19.

Guest Editors

Prof. Dr. Dragan Primorac

Center for Personalized Medicine, St Catherine Hospital, Zagreb, 10000, Croatia; Eberly College of Science, The Pennsylvania State University, University Park, PA 16802, USA

Dr. Marijo Parčina

Institut für Medizinische Mikrobiologie Immunologie und Parasitologie (IMMIP), Universitätsklinikum Bonn, 53127 Bonn, Germany

Deadline for manuscript submissions

closed (31 May 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/108632

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).